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Abstract
Staphylococcus aureus is an important human pathogen that causes wide range of infec-
tious conditions both in nosocomial and community settings. The Gram-positive patho-
gen is armed with battery of virulence factors that facilitate to establish infections in the 
hosts. The organism is well known for its ability to acquire resistance to various antibiotic 
classes. The emergence and spread of methicillin-resistant S. aureus (MRSA) strains which 
are often multi-drug resistant in hospitals and subsequently in community resulted in 
significant mortality and morbidity. The epidemiology of MRSA has been evolving since 
its initial outbreak which necessitates a comprehensive medical approach to tackle this 
pathogen. Vancomycin has been the drug of choice for years but its utility was challenged 
by the emergence of resistance. In the last 10 years or so, newer anti-MRSA antibiotics 
were approved for clinical use. However, being notorious for developing antibiotic resis-
tance, there is a continuous need for exploring novel anti-MRSA agents from various 
sources including plants and evaluation of non-antibiotic approaches.
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1. Introduction
Staphylococcus aureus is a Gram-positive bacterium and causative agent of wide range of 
infectious diseases such as skin infections, bacteremia, endocarditis, pneumonia and food 
poisoning. The organism was originally a leading nosocomial pathogen and afterwards epi-
demiologically distinct clones emerged in community settings. S. aureus expresses number 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
of virulence factors which help to establish infection by facilitating tissue attachment, tis-
sue invasion and evading from host immune response. The ability to acquire resistance to 
multiple antibiotics classes makes S. aureus, a challenging pathogen to treat. Emergence and 
spread of S. aureus strains which are resistant to methicillin, referred to as methicillin-resistant 
S. aureus (MRSA) resulted in high morbidity, high mortality and increased treatment costs. 
Vancomycin remained gold standard drug to tackle these strains for years but the emergence 
of resistance restricted its clinical utility. Newer anti-MRSA antibiotics which were approved 
by U.S. FDA came as respite for clinicians. However, new antibiotic discovery efforts and 
non- antibiotic approaches to tackle MRSA should not be diminished considering the ability 
of the pathogen to acquire resistance to newer drugs quickly after their introduction in clinics.
In this chapter, we present a comprehensive outlook of S. aureus with account on bacteriology, 
pathogenesis, epidemiology, antibiotic resistance and therapeutic approaches.
2. Bacteriology
2.1. Microscopic morphology
S. aureus cells are Gram-positive and appear in spherical shape. They are often in clusters 
resembling bunch of grapes when observed under light microscope after Gram staining. The 
name ‘Staphylococcus’ was derived from Greek, meaning bunch of grapes (staphyle) and 
berry (kokkos) [1]. The scanning electron microscopic observation reveals roughly spherical 
shaped cells with smooth surface [2]. The diameter of the cells ranges from 0.5 to 1.0 μM [3]. 
The transmission electron microscopy of cells shows thick cells wall, distinctive cytoplasmic 
membrane and amorphous cytoplasm [4].
2.2. General cultural and biochemical characteristics
S. aureus is an aerobic and facultative anaerobic organism that forms fairly large yellow or 
white colonies on nutrient rich agar media. The yellow colour of the colonies is imparted by 
carotenoids produced by the organism. The term ‘aureus’ is derived from Latin, which refers 
to the colour of gold [5]. The organism is often haemolytic in blood agar due to production of 
four types of haemolysins (alpha, beta, gamma and delta) [6, 7]. Nearly all isolates of S. aureus 
produce coagulase enzyme, a virulence factor that also helps in identification of the organ-
ism [6, 8]. The organism is salt tolerant, which is able to grow in mannitol-salt agar medium 
containing 7.5% sodium chloride [8]. The organism is catalase positive and oxidase negative.
2.3. Medical laboratory diagnosis
The primary objective in laboratory diagnosis is to identify whether the diagnosed S. aureus 
isolate is methicillin resistant. Since MRSA emerged as problematic pathogen, a systematic 
diagnostic approach is necessary for early diagnosis so that treatment with appropriate 
antibiotics can be initiated as early as possible. For the species identification, slide and tube 
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 coagulase tests, latex agglutination tests and PCR-based tests are used. For detection of MRSA, 
determination of minimum inhibitory concentration (MIC) of methicillin or oxacillin or cefox-
itin using broth micro-dilution method, cefoxitin disk screen, oxacillin agar screen and latex 
agglutination test for PBP2a and molecular methods for detection of mecA are employed [8].
3. General pathogenesis and clinical diseases
3.1. Pathogenesis
The process of S. aureus infections involves five stages. They are (1) colonization, (2) local 
infection, (3) systemic dissemination and/or sepsis, (4) metastatic infections and (5) toxinosis. 
The organism is in carrier state in the anterior nares and can remain so without causing infec-
tions for weeks or months. The colonization proceeds to infection under certain predisposing 
factors such as prolonged hospitalization, immune suppression, surgeries, use of invasive 
medical devices and chronic metabolic diseases. Localized skin abscess develop when the 
organism is inoculated into the skin from a site of carriage. This can further spread and results 
in various clinical manifestations of localized infections such as carbuncle, cellulitis, impe-
tigo bullosa or wound infection. The organism can enter into blood and spread systemically 
to different organs causing sepsis. This haematogenous spread may result in endocarditis, 
osteomyelitis, renal carbuncle, septic arthritis and epidural abscess. Without a blood stream 
infection, specific syndromes can occur due to extra cellular toxins of S. aureus. These are toxic 
shock syndrome, scalded skin syndrome and foot borne gastroenteritis [9].
3.2. Hospital and community infections
S. aureus causes wide range of infections in human. The clinical infections of S. aureus are 
classified into community and nosocomial categories based on origin of infection. These two 
types are distinct in clinical manifestations of the infections, antibiotic susceptibility and the 
genetic background of the infecting S. aureus strains. For decades, S. aureus has been predomi-
nately a nosocomial pathogen and is a leading cause of mortality and morbidity in hospitals. 
However, the community S. aureus infections are in rise. The important clinical S. aureus infec-
tions are bacteraemia, infective endocarditis, skin and soft tissue infections, osteoarticular 
infections and pleuropulmonary infections. Other clinical infections are epidural abscess, 
meningitis, toxic shock syndrome and urinary tract infections [9, 10].
3.3. Virulence factors
S. aureus possess battery of virulence factors. These factors enable the organism to be successful 
as pathogen that causes wide range of human and animal infections. Virulence factors help in 
attachment to host cells, breaking down the host immune shield, tissue invasion, causing sepsis 
and elicit toxin-mediated syndromes. This is the basis for persistent staphylococcal infections 
without strong host immune response [11]. Based on their mechanism of action and role in 
pathogenesis, staphylococcal virulence factors are classified as represented in Table 1 [9, 12].
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Factors Characteristics
Helping attachment to host tissues
Microbial Surface Components Recognizing adhesive 
matrix molecules (MSCRAMM)
Cell surface proteins which interact with host molecules 
such as collagen, fibronectin & fibrinogen, thus, facilitate 
the tissue attachment. Staphylococcal protein A, 
fibronectin-binding proteins A and B, collagen-binding 
protein & clumping factor A & B belong to this family. 
They are also involved in host immune evasion [13].
Breaking/evading the host immunity
Polysaccharide microcapsule Resist the phagocytosis & killing by polymorphonuclear 
phagocyte [14].
Protein A It binds to Fc portion of immunoglobulin, prevents 
opsonization, functions as super antigen & limits the host 
immune response [15].
Panton-Valentine leukocidin (PVL) PVL is found in most of community-associated MRSA 
(CA-MRSA) [16]. PVL belongs to group of membrane 
pores forming proteins. It consists of two protein 
components (LukS-PV and LukF-PV) which act together 
as subunits and form porins on cell membrane of host 
cells, leading to leakage of cell contents and cell death 
[17].
Alpha-toxin (Alpha hemolysin) It was the first bacterial exotoxin to be identified as a 
cell membrane pore former which causes cell leakage & 
death [18].
Chemotaxis-inhibitory protein of S. aureus (CHIPS): CHIPS is an extracellular protein which inhibits the 
chemotaxis functioning of neutrophil and monocytes 
[19].
Tissue invasion
Extracellular adherence protein (Eap) An exoprotein which binds to host cell matrix, plasma 
proteins & endothelial cell adhesion molecule ICAM-1. In 
addition to the roles of adhesion and invasion, it also has 
immune-modulatory activity [20].
Proteases, lipases, nucleases, hyaluronatelyase, 
phospholipase C, metalloproteases (elastase), & 
Staphylokinase
These extracellular enzymes cause tissue destruction and, 
thereby, help in bacterial penetration into tissues.
Induces toxinosis
Enterotoxins S. aureus produces battery of enterotoxins which are 
potent gastrointestinal exotoxins. The Staphylococcal 
food poisoning is an intoxication which results from 
consumption of foods containing sufficient amount of 
preformed enterotoxins [21].
Toxic shock syndrome toxin -1 (TSST-1) TSST-1 & some of enterotoxins are called as pyrogenic 
toxin super antigens. TSST-1 causes toxic shock 
syndrome especially in menstrual women [7].
Exfoliative toxins A and B Serine proteases which selectively recognize and 
hydrolyze desmosomal proteins in the skin. ETs 
cause staphylococca-scalded skin syndrome, a disease 
predominantly affecting infants [22].
Table 1. Virulence factors of S. aureus and its characteristics.
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4. Epidemiology of infections
4.1. Nasal carriage
S. aureus is a commensal and opportunistic pathogen. The anterior nares are the principal 
ecological niche, where the organism colonizes in humans. The nasal carriage of S. aureus 
increases the risk of infection especially in the hospital settings [23]. The average nasal car-
riage of S. aureus could be at 30% of human population [24]. Since, the nasal carriage increases 
the risk of development of surgical site, lower respiratory and blood stream infections in 
hospitals, efforts are made to eliminate the carriage using various strategies. Methods such 
as local application of antibiotics (eg. mupirocin) or disinfectants, administration of systemic 
antibiotics and use of a harmless S. aureus strain (type 502A) which competes for the coloniza-
tion of nares with existing one are employed to decolonize the S. aureus from nares [25–28].
4.2. Emergence and evolution of MRSA
The MRSA are those S. aureus strains carrying a mecA gene, which codes for additional peni-
cillin-binding protein, PBP2a. The beta-lactam antibiotics exert their antibacterial activity by 
inactivation of penicillin-binding proteins (PBPs), which are essential enzymes for bacterial 
cell wall synthesis. However, these antibiotics have only a low affinity towards PBP2a, thus 
this enzyme evades from inactivation and carry out the role of essential PBPs resulting in cell 
wall synthesis and survival of bacteria even in presence of beta-lactam antibiotics. Due to the 
presence of mecA, MRSA are resistant to nearly all beta-lactam antibiotics [29].
Penicillin is the first beta-lactam antibiotic discovered in 1928 and found to be effective 
weapon against S. aureus infections. In 1940s, sooner after its introduction into clinics, there 
were reports of S. aureus strains that were resistant to penicillin [30]. These strains produced 
plasmid-encoded beta-lactamase enzyme (penicillinase) which enzymatically cleaved the 
beta-lactam ring of penicillin rendering the antibiotic inactive [31, 32]. In 1950s, the penicillin 
resistance was restricted to hospital isolates of S. aureus. By late 1960s, more than 80% S. aureus 
isolates, irrespective of community and hospital origin, were resistant to penicillin due to plas-
mid transfer of penicillinase gene (blaZ) and clonal dissemination of resistant strains [33, 34].
Meanwhile, scientists who were challenged with penicillinase-mediated resistance in S. aureus 
discovered methicillin, a semi-synthetic penicillin that withstood the enzymatic degradation 
of penicillinase. Methicillin was introduced into clinics in 1961; however, in less than a year, 
resistance of S. aureus isolates to methicillin (MRSA) was reported [35]. Over the next 10 years, 
increasing number of MRSA outbreaks was reported in different parts of the world especially 
from the European countries [36, 37]. The notable feature of these reports is that, the incidences 
were from hospitals and thus MRSA emerged as a hospital-borne pathogen. The mechanism 
of resistance to beta-lactam antibiotics in these MRSA isolates was uncovered in 1981 [38].
As mentioned earlier, MRSA isolates carry a gene mec A which codes for PBP2a. The gene is 
part of a 21–60 kb mobile genetic element referred to as staphylococcal cassette chromosome 
mecA (SCCmecA). There are two hypotheses that explain the evolutionary origin of MRSA. The 
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single clone hypothesis suggests that the mobile genetic element entered the S. aureus popula-
tion on one occasion and resulted in the formation of a single MRSA clone that has since spread 
around the world. The second and the most agreed hypothesis is that MRSA strains evolved 
number of times by means of the horizontal transfer of the mobile genetic element into phylo-
genetically distinct methicillin-susceptible S. aureus (MSSA) precursor strains [39, 40].
SCCmec elements are highly diverse in their structural organization and genetic content 
(Figure 1) and have been classified into types based on the combination of mec and ccr, which 
share variations (five classes in mec and eight in ccr). To date, at least 11 types of SCCmec ele-
ments have been identified [41–43].
4.3. Health care-associated and community MRSA
4.3.1. Health care-associated MRSA (HA-MRSA)
Health care-associated MRSA (HA-MRSA) are those S. aureus isolates obtained from patients 
2 or more days after hospitalization or with the MRSA risk factors (history of recent hospi-
talization, surgery, dialysis, or residence in a long-term care facility within 1 year before the 
MRSA-culture date or presence of a permanent indwelling catheter or percutaneous medical 
device (e.g. tracheostomy tube, gastrostomy tube or Foley catheter) at the time of culture 
or previous isolation of MRSA [44, 45]. Community-associated MRSA (CA-MRSA) are those 
S. aureus isolates obtained from patients within 2 days of hospitalization and without the 
above-mentioned MRSA risk factors.
Till 1990s, MRSA isolates were predominantly HA-MRSA and were also resistant to non-beta-
lactam antibiotics. The multi-drug resistant phenotype of HA-MRSA was due to presence of 
non-beta-lactam antibiotic-resistant determinants in relatively large SCCmec [46]. During the 
period of 1960s to early 1990s, number of clones of HA-MRSA had spread widely across the 
world and HA-MRSA became endemic in hospitals and emerged as leading nosocomial patho-
gen [47]. The genetic background of these MRSA clones was characterized initially using phage 
typing subsequently by multilocus sequence typing (MLST), pulsed-field gel electrophoresis 
(PFGE), spa typing and SCCmec typing. The analysis of the genetic background of HR-MRSA 
Figure 1. Basic structure of SCCmec. SCCmec constituted by mec gene and ccr gene complexes. The mec gene complex 
encodes PBP2a (mecA) and resistance regulators (mecI and mcR1). The ccr gene complex encodes the integration and 
excision of entire SCC element. The gene complexes are flanked by characteristic nucleotide sequences, inverted repeats 
(IR) and direct repeats (DR), at both ends. J (joining) regions are J1 (between right chromosomal junction and ccr 
complex, J2 (between ccr and mec complexes) and J3 (between mec complex and left chromosomal junctions). Adopted 
from Ref. [41].
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isolates using these methods revealed the spread of early MRSA clone (Archaic clone) which 
contained type I SCCmec and sequence type 250 (ST250) in 1960s and extended into the 1970s 
in the form of Iberian clone. The Iberian clone was sequence type 247 (ST247) which evolved 
from ST250-MRSA by a single point mutation [48]. In the mid to late 1970s, Archaic and Iberian 
MRSA clones declined while, clones with novel SCCmec types II and III had emerged mark-
ing the on-going worldwide pandemic of HA-MRSA in hospitals and health care facilities 
[49, 50]. The lineages of common HA-MRSA clones are represented in Table 2. The rise in the 
prevalence of HA-MRSA throughout the world has been dramatic. In the United States, the 
proportion of MRSA among S. aureus isolates from the hospitalized patients was 2.4% in 1975, 
which increased to 51.6% (ICU patients) and 42% (non-ICU inpatients) by 1998–2003. Similar 
persistently high or increasing rates of MRSA among S. aureus isolates have also been observed 
for health care settings in many other regions of the world [51].
4.3.2. Community-associated MRSA (CA-MRSA)
MRSA isolates obtained from outpatients or from patients within 48 h of hospitalization and if 
they lack HA-MRSA risk factors mentioned earlier are referred to as CA-MRSA [52]. Scattered 
case reports of MRSA infections in healthy population whom had no exposure to health care 
facilities were published in the 1980s and mid-1990s. Beginning in 1993, case series of MRSA 
infection and colonization of patients lacking health care-associated risk factors were reported 
from six continents, in diverse states, nations and regions [51, 53]. The phenotypic and geno-
typic characterization of CA-MRSA isolates revealed the differences between CA-MRSA and 
HA-MRSA strains. While HA-MRSA strains carried a relatively large SCCmec, belonging to 
type I, II or III, CA-MRSA strains carried smaller SCCmec elements, most commonly type 
IV or type V. HA-MRSA strains were resistant to many classes of non-beta-lactam antibiot-
ics, thus display multi-drug resistant phenotypes. CA-MRSA strains were often sensitive to 
non-beta-lactam antibiotics. Another notable feature of CA-MRSA strains was presence of 
genes for the PVL, which was rare among the HA-MRSAs. With respect to clinical cases, 
CA-MRSA infections were prevalent in previously healthy younger patients in contrast to 
HA-MRSA, which cause infections in hospitalized patients. CA-MRSA was often associated 
with skin and skin structure infections while HA-MRSA was implicated in wide range of 
infections such as pneumonia, bacteraemia, and invasive infections [48, 51]. Compared to 
infections caused by HA-MRSA, CA-MRSA infections had been associated with fulminant 
and lethal infections and worse clinical outcomes [49, 53].
Among the various clones of CA-MRSA, ST93, ST80 and ST8 are presently the predominant clones 
in Australia, Europe and the United States, respectively. In the United States, ST8-USA 300 is the 
most wide spread CA-MRSA clone [54], which harbour SCCmec type IV and genes encoding 
PVL. The concern about this clone is high virulence and increase in resistance to non-beta-lactam 
antibiotics [50, 53]. In United Kingdom, EMRSA-15 (ST22) and EMRSA-16 (ST36) are the domi-
nant clones [49]. In Europe, ST80-IV, ST8-IV, ST398-V and ST152-V were commonly reported [55]. 
In Mediterranean countries, the dominant clones are ST80-IV and ST5-IV/V [55, 56].
In the last 10 years, there is a dramatic change in epidemiology of CA-MRSA as they invaded the 
health care settings. In 2008, first case of MRSA isolated from hospitalized patient turned out to 
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be a CA-MRSA which marked the arrival of CA-MRSA into nosocomial settings [57]. Since then, 
hospital outbreaks of S. aureus strains which are phenotypically and genotypically CA-MRSA, 
have been reported many parts of the world [55]. Entry of CA-MRSA into hospitals blurred the 
differences between CA-MRSA and HA-MRSA. The increased reports of CA-MRSA outbreaks 
in hospital suggest that CA-MRSA may eventually displace HA-MRSA in hospitals [58].
Clonal complex Molecular sequence 
type
Common names for  
specific MRSA clones
Comment
CC5 ST5 USA100 and NewYork/Japan 
clone
Most common US health 
care-associated MRSA, 
SCCmecII
ST5 EMRSA-3 SCCmecI
ST5 USA800/Pediatric clone Prevalent in Argentina, 
Colombia, United States, 
SCCmecIV
ST5 HDE288/Pediatric clone SCCmecVI
CC8 ST250 Archiac First MRSA clone 
identified, COL strain as an 
example; SCCmecI
ST247 Iberian clone and EMRSA-5 Descendant of COL-type 
strains, SCCmecIII
ST239 Brazilian/Hungarian clone SCCmecIII
ST239 EMRSA-1 Eastern Australian 
epidemic clone of 1980s, 
SCCmecIII
ST8 AUS-2 and Aus-3 SCCmecII
ST8 Irish-1 Common nosocomial 
isolate in the 1990s in 
Europe and the United 
States
ST8 USA500 and EMRSA-2-6 SCCmecIV
CC22 ST22 EMRSA-15 International clone, 
prominent in Europe and 
Australia, SCCmecIV
CC30 ST36 USA200 and EMRSA-16 Single most abundant 
cause of MRSA infections 
in UK; second most 
common cause of MRSA 
infections in US hopsitals 
in 2003, SCCmecII
CC45 ST45 USA600 and Berlin SCCmecII
Table 2. The lineages of common HA-MRSA (based on Ref. [49]).
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5. Antibiotic resistance
5.1. Beta-lactam resistance
5.1.1. Penicillin resistance
The first beta-lactam antibiotic penicillin G was discovered in 1928 by Alexander Fleming and 
the drug was used in human as chemotherapeutic agent in 1941 [59]. The antibiotic was potent 
against Gram positive pathogens [60] and a power weapon against Staphylococcal infections. 
However, first reports of S. aureus strains that were resistant to penicillin appeared after a year 
of its clinical use [30]. Such penicillin-resistant isolates carried a plasmid gene, blaZ which 
encoded a beta-lactamase enzyme, referred to as penicillinase [33, 34]. The enzyme is capable 
of cleaving the beta-lactam ring of penicillin resulting inactivation of the antibiotic [31, 32].
The emergence and spread of penicillinase-mediated resistance in S. aureus is referred to as 
first wave of resistance. This has spread in alarm proportions and became pandemic in the 
1960s. About 80% of both community and hospital acquired S. aureus isolates were resistant 
to penicillin by late 1960s [33, 49]. By early 2000s, more than 90% of Staphylococcal isolates 
produced penicillinase enzyme irrespective of their community or hospital origin [34].
5.1.2. Methicillin resistance
As discussed earlier, the penicillinase resistance in S. aureus was countered by the discovery of 
methicillin, penicillinase-stable semisynthetic penicillin. The drug was introduced into clin-
ics in 1961 and subsequently strains showing methicillin resistance (MRSA) was reported in 
the same year [35]. After the initial report, MRSA clones spread rapidly across the world but 
restricted to nosocomial settings. This is referred to as second wave of beta-lactam resistance 
in S. aureus [40]. As discussed earlier, methicillin resistance was mediated by the presence of 
mecA gene. The therapeutic outcome of MRSA infections was worse than methicillin sensitive 
S. aureus (MSSA) due to the underlying comorbid factors such as old age, immune suppres-
sion and, importantly, lack of effective antibiotics to treat MRSA, which were often multi-
drug resistant [34]. The rise in MRSA infections in hospitals resulted in high morbidity and 
mortality and increase in cost of health care [61, 62].
The third wave of beta-lactam resistance in S. aureus began with reports of MRSA infections 
in community in early 1990s. As discussed earlier, these strains were phenotypically and 
genetically distinct from MRSA isolates from hospitalized patients, resulting in definitions of 
HA-MRSA and CA-MRSA [51, 53]. In the last decade, community MRSA strains invaded the 
hospital settings and the difference between HA and CA MRSA is now blurred [58].
5.2. Quinolones resistance
Nalidixic acid, the prototype quinolone and the second generation quinolones (e.g. cipro-
floxacin and norfloxacin) are predominately active towards Gram negative bacteria while 
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third generation (e.g. levofloxacin) and fourth generation (e.g. moxifloxacin, gemifloxacin) 
quinolones exhibited improved and greater activity against Gram-positive bacteria [63–65]. 
Quinolones exert their antibacterial action by inhibiting bacterial topoisomerases (topoisom-
erase IV and DNA Gyrase), which are essential for relieving DNA super coiling and separa-
tion of concatenated DNA strands [66]. The resistance to quinolones in S. aureus arises in 
stepwise manner, due to point mutations primarily in GrlA subunit of topoisomerase IV and 
GyrA subunit of Gyrase. Additional mechanism by which S. aureus become resistant to qui-
nolones is by expression of NorA efflux pumps [67].
The quinolone resistance in S. aureus is mostly associated with methicillin resistance though 
the mechanism of resistance and encoding genes are altogether different from each other. 
This could be due to higher usage of quinolones in hospital settings where the HA-MRSA 
prevalence is high resulting in selection of quinolone resistance [68–70]. In year 2008, the 
fluoroquinolone resistance among MRSA isolates implicated in acute bacterial skin and skin 
structure infections (ABSSSIs) in hospitals was at 70.3%. Due to such high level of quinolone 
resistance among MRSA in hospital settings, even third- and fourth-generation quinolones 
have not been considered for treatment of MRSA [71]. With respect to CA-MRSA, though 
they were susceptible to non-beta-lactam antibiotics including quinolones, the scenario 
has changed in recent years, with the rise in incidence of CA-MRSA infections which were 
multi-drug resistant [72].
5.3. Vancomycin resistance
Vancomycin, a glycopeptide antibiotic, was discovered from a microbial source (Streptomyces ori-
entalis) in 1952. The drug was approved for clinical use in 1958; however, it was eclipsed by methi-
cillin and other anti-staphylococcal penicillins which were considered less toxic than vancomycin 
and equally efficacious against penicillin-resistant Staphylococci [73]. Beginning early 1980s, there 
was sudden increase in vancomycin usage due to rise in HA-MRSA infections and emergence of 
pseudomembranous enterocolitis cause by Clostridium difficile in hospitalized patients [73–75]. 
Clinical efficacy of vancomycin efficacy in treatment of MRSA infections was well established 
over the period of time, thus the drug emerged as workhorse anti-MRSA drug [76].
5.3.1. Vancomycin intermediate S. aureus
The antibacterial activity of vancomycin is mediated by its binding to the C-terminal 
D-Ala-D-Ala residue of the peptidoglycan precursor, and formation of non-covalent com-
plex, thereby, prevents the use of the precursor in bacterial cell wall synthesis [77, 78]. 
Three decades after its introduction into clinics, no clinical resistance to vancomycin was 
reported. The first report of a MRSA strain showing reduced susceptibility to vancomycin 
was reported in 1997. The vancomycin MIC against this strain (Mu50) was 8 mg/L, thus, 
designated as intermediate sensitive category. The strain had thickened cell wall when 
observed under electron microscopy and did not carry vanA or vanB genes as found in 
vancomycin-resistant enterococci (VRE) [79]. Subsequently, there were more reports of 
clinical infections due to MRSA strains with decreased vancomycin susceptibility similar 
to that of Mu50 strain. The S. aureus strains with a MIC range of 4–8 mg/L are referred to as 
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 vancomycin intermediate S. aureus (VISA). There were strains, which showed vancomycin 
MIC of 2 mg/L but had subpopulation with vancomycin MIC of 4–8 mg/L. These strains are 
referred to as hetero VISA (hVISA) [80, 81].
The genetic basis of emergence of VISA appears complex. The genetic analysis of VISA strains 
identified mutations in determinants that control the biosynthesis of bacterial cell wall and/
or mutations in the ribosomal gene rpoB [82]. The increased MRSA infection in hospitals has 
led to extensive use of vancomycin resulting in the selection of MRSA strains with reduced 
vancomycin susceptibility [83]. The study on prevalence of hVISA and VISA has met with the 
problem of accurate detection of decreased susceptibility to vancomycin. Different diagnostic 
methods showed variable sensitivity and specificity leading to contradictory reports in prev-
alence [80, 84–86]. During 2010–2014, the prevalence rates of hVISA and VISA among MRSA 
strain were at 7.01% and 7.93%, respectively [87]. The emergence and increased incidence of 
hVISA and VISA has limited the therapeutic use of vancomycin in the treatment of MRSA 
infections in hospital. However, by optimizing the dose regimen and drug delivery, thereby, 
achieving the desired blood plasma concentration which would give the clinical efficacy is 
the way forward in preserving the clinical utility of vancomycin [88, 89].
5.3.2. Vancomycin-resistant S. aureus
S. aureus strains which are referred to as hVISA and VISA are not considered resistant based 
on vancomycin susceptibility breakpoint (vancomycin MIC of 8 mg/L) defined by clinical lab-
oratory standards institute (CLSI). Unlike VRE, these strains do not carry vanA or vanB type 
of genes to confer resistance to vancomycin. In 2002, first report of a S. aureus strain showing 
vancomycin MIC of >128 mg/L was published. The strain was methicillin resistant and carried 
vanA gene which was responsible for high-level resistance to vancomycin [90]. This report 
was followed by sporadic incidences of isolation of S. aureus strains with resistance to vanco-
mycin [91]. All these strains showed high vancomycin MIC (>8 mg/L) and are referred to as 
vancomycin-resistant S. aureus (VRSA).
VRSA strains carried copies of the transposon Tn1546, which was acquired from vancomy-
cin-resistant Enterococcus faecalis. The transposon which mediates the VanA-type resistance, 
encodes a dehydrogenase (VanH), which reduces pyruvate to D-Lac, and the VanA ligase, 
which catalyzes the formation of an ester bond between D-Ala and D-Lac. The resulting 
D-Ala-D-Lac depsipeptide replaces the D-Ala-D-Ala dipeptide in peptidoglycan synthesis, 
a substitution that decreases the affinity of the molecule for vancomycin and other glycopep-
tide antibiotic, teicoplanin, considerably [92, 93].
5.4. Resistance to other antibiotics
Since HA-MRSA strains are often MDR phenotype, drugs such as sulphonamides, tetracy-
clines, aminoglycosides, chloramphenicol and clindamycin were sidelined due to lack of 
activity, while vancomycin remained the mainstay of therapy. Resistance to sulphonamides 
and trimethoprim [94], tetracyclines [95–97], aminoglycosides [98–100], chloramphenicol [101] 
and clindamycin [102], occurring in S. aureus especially among MRSA was widely reported.
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6. Therapeutic approach
Therapeutic approach to S. aureus infections depends on the type of infection, patient age, 
clinical manifestation of the disease, co-morbidity, antibacterial susceptibility of infecting 
organism and hospitalization. Various drugs as single agent and drug combinations have 
been used to treat S. aureus infection. In general, management of infections due to MRSA is 
difficult compared to that of MSSA. There are guidelines and reviews to help in the treatment 
of community and hospital infections of MRSA.
6.1. Topical anti-MRSA drugs
6.1.1. Mupirocin
Mupirocin is used as topical antibiotic to treat impetigo due to S. aureus and S. pyogenes [103]. 
The drug is also used for nasal decolonization of S. aureus [27]. Mupirocin belongs to monoxy-
carbolic acid class and it exerts antibacterial action by binding to isoleucyl t-RNA synthetase, 
thereby, inhibiting the protein synthesis [104]. The antibiotic shows excellent activity against 
Staphylococci and most Streptococci [105]. Clinical efficacy of mupirocin ointment in treating 
S. aureus superficial skin infections and wound infections was established [106–108]. Various 
reports also demonstrated effectiveness of mupirocin in nasal decolonization of S. aureus 
[25, 109, 110] that is a risk factor for MRSA infections in nosocomial settings.
6.1.2. Fusidic acid
Fusidic acid is an antibiotic, which belongs to a class referred to as fusidanes. Chemically it 
is a tetracyclic triterpenoid [111] and it binds to bacterial elongation factor G (EF-G), which 
results in impaired translocation process and inhibition of protein synthesis [112]. It has 
potent activity against S. aureus and clinically used in treatment of mild to moderately 
severe skin and soft-tissue infections, for example, impetigo, folicullitis, erythrasma, furun-
culosis, abscesses and infected traumatic wounds [113]. The efficacy of fusidic acid ointment 
in treatment of S. aureus infections is widely reported [114, 115]. The drug has also been used 
systemically to treat invasive S. aureus infections but its efficacy was questioned [116].
6.2. Systemic anti-MRSA drugs
6.2.1. Vancomycin
As discussed earlier, vancomycin remained the mainstay of therapy against MRSA infec-
tions in hospitalized patients for decades. Though the antibiotic was available for clinical 
use since 1958, it gained prominence among clinicians only after the surge in nosocomial 
MRSA infections in 1980s [73, 75]. Numerous reports documented the clinical efficacy of 
vancomycin in treating various MRSA infections in hospitalized patients [116–120]. The 
emergence and spread of hVISA and VISA strains has threatened the clinical utility of vanco-
mycin. In addition, over the years, the mean MIC of vancomycin against susceptible MRSA 
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Newer-MRSA drug Year of approval Class Source Mode of action Route of 
administration
References
Linezolid 2000 Oxazolidinone Synthetic Inhibition of  
protein synthesis
Oral & intra-venous [126, 127]
Daptomycin 2003 Cyclic lipopeptide Streptomyces 
oseosporus
Cell membrane 
depolarization
Intra-venous [128, 129]
Tigecycline 2005 Glycylcyclines 
(Tetracyclines)
Semisynthetic Inhibition of  
protein synthesis
Intra-venous [130, 131]
Ceftaroline 2010 Cephalosporin 
(Beta-lactam)
Semisynthetic Inhibition of cell  
wall synthesis
Intra-venous [132, 133]
Telavancin 2013 Lipoglycopeptide Semisynthetic Inhibition of cell 
wall synthesis & 
cell membrane 
depolarization
Intra-venous [134, 135]
Tedizolid 2014 Oxazolidinone Synthetic Inhibition of  
protein synthesis
Oral & intra-venous [136, 137]
Dalbavancin 2014 Lipoglycopeptide Semisynthetic Inhibition of cell  
wall synthesis
Intra-venous [138, 139]
Oritavancin 2014 Lipoglycopeptide Semisynthetic Inhibition of cell 
wall synthesis & 
cell membrane 
depolarization
Intra-venous [140, 141]
Table 3. Newer anti-MRSA drugs.
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 populations has increased but within the susceptible range. This phenomenon is referred to 
as vancomycin MIC creep. There has been poor response to vancomycin therapy in patients 
infected with vancomycin-susceptible MRSA isolates which had vancomycin MIC at the 
higher end of susceptible range (2 mg/L) [121, 122]. Optimizing the dose regimen and drug 
delivery, in order to achieve the desired blood plasma concentration which would give the 
clinical efficacy is the way forward in preserving the clinical utility of vancomycin [91, 92].
6.2.2. Newer anti-MRSA drugs
The problem of MRSA infections in hospitals and lack of effective antibiotics other than van-
comycin to treat them necessitated the discovery of novel anti-MRSA drugs. The continued 
efforts of researchers in discovering novel anti-MRSA drugs fructified resulting in arrival of 
number of newer anti-MRSA drugs for clinical use in the last 15 years [78, 123–125]. The follow-
ing Table 3 lists the newer anti-MRSA drugs that were approved by U.S. FDA for clinical use.
7. Alternative therapeutic approach
Apart from chemotherapeutic approach to tackle the S. aureus infection, alternatives such 
as agents which inhibit the virulent factors expression and vaccines have been investigated. 
Various phytochemical are also found to have anti-MRSA activity. All these are at investiga-
tional stages and more research is necessary to bring promising candidates for clinical usage.
7.1. Anti-virulence agents
Clinical use of agents which are not conventional antibiotics but able to inhibit the expression 
or function of the virulence factors, rendering the bacteria non-pathogenic is considered an 
alternative approach to tackle MRSA. Stripping microorganisms of their virulence properties 
without threatening their existence may offer a reduced selection pressure for drug-resistant 
mutations. Virulence-specific therapeutics would also avoid the undesirable dramatic altera-
tions of the host microbiota that are associated with current antibiotics [142, 143].
Accessory gene regulator (agr)-mediated quorum sensing system of S. aureus plays a central 
role in pathogenesis of Staphylococci. Scientists identified small molecules which inhibited 
the agr system [144–146]. Active and passive immunization strategies targeting the virulence 
factors of S. aureus have also been explored [147].
7.2. Plants
Plants have immune system and other defensive mechanisms against microorganisms that 
cause plant diseases. Hence, the plants with huge diversity provide a vast source for exploration 
of anti-MRSA phytochemicals. In vitro Anti-MRSA activity of crude extracts of medicinal plants 
has been extensively reported [148]. Various phytochemicals such as β-asarone, Mansonone F, 
prenylated flavonoids and thymoquinone showed in vitro anti-MRSA activity [149–152].
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